WFRF:(Isma Nazim)
Sökning: WFRF:(Isma Nazim) > Rate and risk facto...
- 17 av 21
- Föregående post
- Nästa post
- Till träfflistan
Rate and risk factors for thromboembolism and major bleeding in adults with congenital heart disease taking vitamin K antagonist therapy
-
- Samarai, Daniel (författare)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Lindstedt, Sandra (författare)
- Lund University,Lunds universitet,Thoraxkirurgi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,DCD transplantation av lungor,Forskargrupper vid Lunds universitet,NPWT teknologin,Klinisk och experimentell lungtransplantation,WCMM- Wallenberg center för molekylär medicinsk forskning,Thoracic Surgery,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,DCD transplantation of lungs,Lund University Research Groups,NPWT technology,Clinical and experimental lung transplantation,WCMM-Wallenberg Centre for Molecular Medicine,Skåne University Hospital
-
- Isma, Nazim (författare)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
- visa fler...
- visa färre...
- (creator_code:org_t)
- Elsevier BV, 2022
- 2022
- Engelska.
- Ingår i: Thrombosis Update. - : Elsevier BV. - 2666-5727. ; 9
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Background: The risk of adults with a congenital heart defect (ACHD) developing heart failure, stroke, arrhythmias, and the need for valve replacement is increased compared to healthy peers. Evidence for the use of novel oral anticoagulants (NOAC) in this patient group is still lacking and vitamin K antagonists (VKA) are the primary choice for patients with a mechanical valve. The present aim was to determine the rate of thromboembolic and major bleeding events in ACHD patients on VKA therapy. Methods: This was a retrospective study on ACHD patients on VKA treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden. Results: 213 patients were included with a mean age of 50 years (±18) years and a mean follow-up of 6.6 years (±3.3 years), 16% had complex defects and 41% had valvular VKA therapy indication. In total, 34 complications were registered, of which 14 were thromboembolic events and 20 were major bleeding events. The rate of thromboembolism and major bleeding events was 1.0 (95% CI: 0.6–1.6) and 1.4 (95% CI: 0.9–2.2) per 100 patient-years, respectively. Forty-three patients died during the study period. The mortality rate was 3.1 per 100 patient-years (95% CI: 2.2–4.1). Conclusion: We found a low rate of thromboembolic events and major bleeding events for low-moderate risk ACHD patients with good quality of VKA anticoagulation. The target of TTR>65% for ACHD patients is recommended.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Adult congenital heart disease
- Anticoagulant therapy
- International normalized ratio
- Oral vitamin K antagonists
- Time in therapeutic range
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
- 17 av 21
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Samarai, Daniel
- Lindstedt, Sandr ...
- Isma, Nazim
- Hlebowicz, Joann ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- Thrombosis Updat ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
